Hexyl Aminolevulinate
Tóm tắt
▴ Hexyl aminolevulinate, the hexyl ester of 5-aminolevulinic acid, is a photosensitising agent designed to enhance the detection of bladder cancer tumours, in particular highly malignant carcinoma in situ (CIS). ▴ After cellular uptake, hexyl aminolevulinate and/or hydrolysed 5-aminolevulinic acid enter the haem biosynthetic pathway and induce accumulation of the photoactive compound protoporphyrin IX (PpIX) in malignant as opposed to nonmalignant cells. PpIX emits red fluorescence when illuminated under blue light. ▴ Blue-light fluorescence cystoscopy with hexyl aminolevulinate (hexyl aminolevulinate cystoscopy) was more effective than standard (white-light) cystoscopy for detecting non-muscle-invasive (‘superficial’) disease in two European, multicentre, phase III trials, which evaluated hexyl aminolevulinate cystoscopy as an adjunct to standard cystoscopy in patients with known or suspected bladder cancer. ▴ In one trial, hexyl aminolevulinate cystoscopy detected 96% of the patients with CIS; it identified 28% more patients with CIS than standard cystoscopy. In the other trial, 17% of patients were selected to receive more complete treatment following hexyl aminolevulinate cystoscopy than standard cystoscopy, because of the improved tumour detection rate. ▴ Hexyl aminolevulinate cystoscopy is well tolerated as an adjunct to standard cystoscopy; adverse events were those typically associated with standard cystoscopy/biopsy (e.g. postoperative pain).
Tài liệu tham khảo
Kirkali Z, Chan T, Manoharan M. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005 Dec; 66 (6 Suppl. 1): 4–34
Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published erratum appears in CA Cancer J Clin 2005; 55: 259]. CA Cancer J Clin 2005; 55: 10–30
Sawzcuk IS. Overview of superficial bladder cancer. In: Diag-nostic and treatment issues in superficial bladder cancer monograph [online]. Available from URL: http://www.project-sinknowledge.com [Accessed 2006 Jan 31]
National Comprehensive Cancer Network. Clinical practice guidelines in oncolology: bladder cancer (version 1.2006) [online]. Available from URL: http://www.nccn.org/professionals/physicians_gls/PDF/bladder.pdf [Accessed 2006 Jan 19]
Sonpavde G. Bladder cancer update: current evaluation methods and standard of care [online]. Postgrad Med 2005; 118 (4). Available from URL: http://www.postgradmed.com [Accessed 2006 Jan 31]
van der Meijden APM. Bladder cancer. BMJ 1998 Nov 14; 317: 1366–9
Bassi P, De Marco V, De Lisa A, et al. Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int 2005; 75(3): 193–200
Zaak D, Karl A, Knuchel R, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int 2005 Aug; 96(2): 217–22
van der Meijden, Sylvester R, Oosterlinck W, et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005; 48: 363–71
van der Meijden A, Oosterlinck W, Brausi M, et al. Significance of bladder biopsies in Ta, T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol 1999 Apr; 35(4): 267–71
Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stages TaT1 transitional cell carcinoma of the bladder: a combined analysis of 7 EORTC studies. Eur Urol 2002; 41: 523–31
Pirtskalaishvili G, Konety BR, Getzenberg RH. Update on urine-based markers for bladder cancer. Postgrad Med 1999 Nov; 106(6): 85–94
Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004 Jan; 171(1): 135–8
Koenig F, McGovern FJ, Larne R, et al. Diagnosis of bladder carcinoma using protoporphyrin IX fluoresence induced by 5-aminolaevulinic acid. BJU Int 1999 Jan; 83(1): 129–35
Zaak D, Hungerhuber E, Schneede P, et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 2002; 95: 1234–8
Riedl CR, Daniltchenko D, Koening F, et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001 Apr; 165(4): 1121–3
Filbeck T, Pichlmeier U, Knuechel R, et al. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumours. J Urol 2002 Jul; 168(1): 67–71
Marti A, Lange N, van den Bergh H, et al. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J Urol 1999 Aug; 162(2): 546–52
Lange N, Jichlinski P, Zellweger M, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 1999 Apr; 80(1–2): 185–93
Marti A, Jichlinski P, Lange N, et al. Comparison of aminolevu-linic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003 Aug; 170 (2 Pt 1): 428–32
Jichlinksi P, Marti A, Aymon D, et al. First experience of hexylester aminolevulinic acid induced fluorescence cystoscopy in patients with superficial bladder cancer [abstract no. 644]. J Urol 2002; 167 (4 Suppl.): 160
Kloek J, Akkermans W, Beijersbergen van Henegouwen GM. Derivatives of 5-aminolevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin. Photochem Photobiol 1998 Jan; 67(1): 150–4
De Rosa FS, Lopez RFV, Thomazine JA, et al. In vitro metabolism of 5-ALA esters derivatives in hairless mice skin homogenate and in vivo PpIX accumulation studies. Pharm Res 2004; 21(12): 2247–52
Hexvix (hexaminolevulinate): summary of product characteristics. Oslo: Photocure ASA, 2005 Mar 1
Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005 Sep; 174(3): 862–6; discussion 866
Gomella LG, Barton Grossman H, Presti JC, et al. The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of carcinoma in situ of the urinary bladder [abstract]. 99th Annual Meeting of the American Urological Society; 2004 May 8–13; San Francisco (CA)
Barton Grossman H, Gomella LG, Fradet Y, et al. The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of stage Ta/T1 urothelial cancer in the urinary bladder [abstract]. 99th Annual Meeting of the American Urological Society; 2004 May 8–13; San Francisco (CA)
Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer. A multicenter study. J Urol 2003 Jul; 170(1): 226–9
Data on file. Photocure ASA, 2006
Witjes JA, Moonen PM, van der Heijden AG. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective phase II study. Eur Urol 2005 Mar; 47(3): 319–22
Loidl W, Schmidbauer J, Susani M, et al. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol 2005 Mar; 47(3): 323–6
Photocure ASA. Hexvix® NDA submitted to FDA [media release]. 2005